Idhifa Enasidenib IDH2 Inhibitor Acute Myeloid Leukemia Review 2026
Author: Critical Kare PharmaHematology Desk
On October 27, 2026, leukemia research groups highlighted Idhifa® (Enasidenib 50 mg and 100 mg film-coated tablets) developed by Celgene / Bristol Myers Squibb as the cornerstone targeted differentiation therapy for IDH2-mutated relapsed/refractory AML.
Idhifa allosterically binds mutant IDH2 homodimers, halting the abnormal oncometabolite 2-hydroxyglutarate (2-HG) production and releasing leukemic blasts from differentiation arrest into functional, mature myeloid cells.
Through Critical Kare Pharma, certified genuine packs of Idhifa Enasidenib Tablets are accessible worldwide via GDP-certified delivery.
Oncogenic Metabolism & Differentiation Reversal
- Targeting R140 and R172 Mutations: Selectively inhibits mutant IDH2 variants, decreasing serum and marrow 2-HG levels by >90%.
- Phase 1/2 Clinical Trial: 40.3% overall response rate with durable complete remissions in heavily pretreated refractory AML.
- Differentiation Syndrome Management: Prompt recognition of fever, dyspnea, and pulmonary infiltrates; immediate treatment with dexamethasone 10 mg IV every 12 hours.
Global Supply Access via Critical Kare Pharma
Coordinated under international named-patient import corridors with rapid 4–8 day worldwide courier dispatch.
